FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	ourden							

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SMITH IAN F					VI	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								(Check	all app	olicable)		Issuer Owner r (specify	
(Last)		(First)	(Middle)											X	belov	N) .	belo		
C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 05/17/2011										EVP	& CFO		
130 WAVERLY ST					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE MA 02139													X	Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)		(State)	(Zip)																
		Ta	able I - N	lon-Deriv	ative	Sec	uritie	s Ac	quire	d, Di	sposed o	f, or B	enefic	ially	Owne	ed			
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/Y				Execution Date,				s Acquired (A) or f (D) (Instr. 3, 4 ar		nd 5) Secui Bene		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
									Code	v	Amount	(A) or (D)	Price		Transa	action(s) 3 and 4)		(111511.4)	
Common Stock 05/17/20:				011	11		S ⁽¹⁾		409	D	\$56.5	56.58(2)(3)		10,177	D				
Common Stock 05/17/20:				011	11		S ⁽¹⁾		300	D	\$57.3	57.32 ⁽³⁾⁽⁴⁾		39,877	D				
Common Stock																5,050	I	401(k)	
			Table II								osed of, convertib				vned				
Derivative Conversion Date Execusecurity or Exercise (Month/Day/Year) if any			emed tion Date, n/Day/Year)	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amount or Number of Title Shares		Deri Secu (Inst	ivative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Mr.\ Smith's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. Open market sales reported on this line occurred at a weighted average price of \$56.58 (range \$56.34 to \$56.97).
- 3. Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$57.32 (range \$57.00 to \$57.60).

Remarks:

Kenneth S. Boger, Attorney-In-

05/18/2011

<u>Fact</u>

** Signature of Reporting Person

son Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.